Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Ciclosporin A
Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil.
In contrast, if concomitant CsA treatment is stopped, an increase in MPA AUC of around 30% should
be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures
by 30-50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with
patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section
4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to
one of the immunosuppressants which does not interfere with MPA’s enterohepatic cycle.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ciclosporin A
Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil.
In contrast, if concomitant CsA treatment is stopped, an increase in MPA AUC of around 30% should
be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures
by 30 - 50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with
patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section
4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to
one of the immunosuppressants which does not interfere with MPA’s enterohepatic cycle.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ciclosporin A
Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil.
In contrast, if concomitant CsA treatment is stopped, an increase in MPA AUC of around 30% should
be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures
by 30 - 50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with
patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ciclosporin A
Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil.
In contrast, if concomitant CsA treatment is stopped, an increase in MPA AUC of around 30% should
be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures
by 30 - 50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with
patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section
4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to
one of the immunosuppressants which does not interfere with MPA’s enterohepatic cycle.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 37e7bee8f6173d9521bbabaed00f0a13c25fa99b099abd87183a65b6eeb2ef01 · Zeichen 2040–2712 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.